Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG known ✓ | P37231 | 13/20 | 0.53 |
| ▸ | CA2 known ✓ | P00918 | 1/20 | 0.47 |
| ▸ | MPC2 | O95563 | 1/20 | 0.48 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | FFAR1 | O14842 | 5/20 | 0.48 |
| ▸ | PPARA | Q07869 | 4/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6064786 | 1.00 | PPARG (0.53) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL1130792 | 0.99 | PPARG (0.54) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL6544486 | 0.95 | PPARG (0.48) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6543635 | 0.94 | PPARG (0.49) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL4177074 | 0.93 | PPARG (0.51) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| SCHEMBL6896704 | 0.92 | PPARG (0.51) | PPARGMPC2CYP2C8CYP2C9FFAR1 | |
| Hydrochloric Acid SCHEMBL6701459 | 0.91 | PPARG (0.47) | PPARGFFAR1PPARACYP3A4RXRA | |
| Hydrochloric Acid SCHEMBL7248266 | 0.90 | FFAR1 (0.48) | PPARGFFAR1PPARACYP3A4RXRA | |
| Hydrochloric Acid SCHEMBL6544449 | 0.89 | PPARG (0.46) | PPARGFFAR1PPARA | |
| SCHEMBL7243299 | 0.89 | FFAR1 (0.49) | PPARGFFAR1PPARACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088462-A1 | Pharmaceutical Composition for Enhancing Adiponectin Production | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-02 | — | — | US | claimed |
| EP-1990053-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ADIPONECTIN PRODUCTION | Daiichi Sankyo Company, Limited (JP) | 2008-11-12 | — | — | EP | claimed |
| US-20070287685-A1 | Medicinal composition containing FBPase inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-12-13 | — | — | US | claimed |
| EP-1180519-B1 | HYDROCHLORIDE OF FUSED-HETEROCYCLE COMPOUND | SANKYO CO (JP) | 2005-05-04 | — | — | EP | claimed |
| US-20020111373-A1 | Hydrochloride salt of a fused heterocyclic compound | SANKYO COMPANY, LIMITED (JP) | 2002-08-15 | — | — | US | claimed |
| US-20090088462-A1 | Pharmaceutical Composition for Enhancing Adiponectin Production | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-04-02 | — | — | US | disclosed |
| EP-1990053-A1 | PHARMACEUTICAL COMPOSITION FOR ENHANCING ADIPONECTIN PRODUCTION | Daiichi Sankyo Company, Limited (JP) | 2008-11-12 | — | — | EP | disclosed |
| EP-1905450-A1 | PHARMACEUTICAL COMPOSITION CONTAINING PPAR GAMMA AGONIST | Daiichi Sankyo Company, Limited (JP) | 2008-04-02 | — | — | EP | disclosed |
| US-20070287685-A1 | Medicinal composition containing FBPase inhibitor | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2007-12-13 | — | — | US | disclosed |
| US-7199139-B2 | Medicinal compositions containing diuretic and insulin resistance-improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-04-03 | — | — | US | disclosed |
| US-20070049515-A1 | Therapeutic agent for diabetes containing insulin resistance improving agent | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1354602-B1 | MEDICINAL COMPOSITIONS CONTAINING DIURETIC AND INSULIN RESISTANCE-IMPROVING AGENT | SANKYO CO (JP) | 2006-10-04 | — | — | EP | disclosed |
| US-20030008907-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | SANKYO COMPANY, LIMITED (JP) | 2003-01-09 | — | — | US | disclosed |
| US-20020137776-A1 | Therapeutic and prophylactic agents for neoplasms | SANKYO COMPANY, LIMITED (JP) | 2002-09-26 | — | — | US | disclosed |
| US-20020111373-A1 | Hydrochloride salt of a fused heterocyclic compound | SANKYO COMPANY, LIMITED (JP) | 2002-08-15 | — | — | US | disclosed |
| EP-1197211-A1 | PREVENTIVE AND THERAPEUTIC AGENTS FOR CANCER | Sankyo Company, Limited (JP) | 2002-04-17 | — | — | EP | disclosed |
| EP-1191019-A1 | INTERMEDIATES FOR THE SYNTHESIS OF BENZIMIDAZOLE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | Sankyo Company, Limited (JP) | 2002-03-27 | — | — | EP | disclosed |
| EP-1180519-A1 | HYDROCHLORIDE OF FUSED-HETEROCYCLE COMPOUND | Sankyo Company, Limited (JP) | 2002-02-20 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| JP-2001039976-A | HYDROCHLORIDE OF CONDENSED HETEROCYCLIC COMPOUND | SANKYO CO LTD | 2001-02-13 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020137776-A1 | Therapeutic and prophylactic agents for neoplasms | VHL, TP53, BRCA1 | PPARG 1300/4885CA2 126/4885MPC2 2705/4885 |
| US-20030008907-A1 | Intermediates for the synthesis of benzimidazole derivatives and a process for the preparation thereof | H1-4, H1-3, GCK | PPARG 1269/4885CA2 40/4885MPC2 837/4885 |
| US-20070049515-A1 | Therapeutic agent for diabetes containing insulin resistance improving agent | GPR119, IAPP, INSR | PPARG 82/4885CA2 2151/4885MPC2 311/4885 |
| US-20090088462-A1 | Pharmaceutical Composition for Enhancing Adiponectin Production | ADIPOR1, ADIPOR2, FABP4 | PPARG 37/4885CA2 4235/4885MPC2 1615/4885 |
| US-20020111373-A1 | Hydrochloride salt of a fused heterocyclic compound | SLC5A1, SLC5A2, SLC2A8 | PPARG 1242/4885CA2 940/4885MPC2 983/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.